Brokerages Set Biohaven Ltd. (NYSE:BHVN) PT at $62.75

Shares of Biohaven Ltd. (NYSE:BHVN) have received a consensus rating of “Buy” from the fourteen analysts that are covering the stock, Marketbeat reports. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $63.00.

A number of brokerages have weighed in on BHVN. Bank of America upped their price objective on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. upped their price objective on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research report on Thursday, October 3rd. TD Cowen boosted their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Jefferies Financial Group began coverage on shares of Biohaven in a research note on Monday, September 16th. They set a “buy” rating and a $57.00 target price for the company. Finally, Sanford C. Bernstein boosted their target price on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 24th.

Insider Activity at Biohaven

In other news, Director Gregory Bailey bought 5,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. This trade represents a 0.31 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John W. Childs bought 21,052 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the acquisition, the director now directly owns 21,052 shares in the company, valued at $999,970. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biohaven

Several institutional investors and hedge funds have recently bought and sold shares of BHVN. DNB Asset Management AS acquired a new position in shares of Biohaven in the 2nd quarter worth approximately $285,000. CWM LLC lifted its holdings in shares of Biohaven by 1,893.4% in the 2nd quarter. CWM LLC now owns 14,552 shares of the company’s stock worth $505,000 after acquiring an additional 13,822 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Biohaven by 114.6% in the 2nd quarter. SG Americas Securities LLC now owns 25,255 shares of the company’s stock worth $877,000 after acquiring an additional 13,485 shares during the last quarter. Oak Ridge Investments LLC lifted its holdings in shares of Biohaven by 197.6% in the 2nd quarter. Oak Ridge Investments LLC now owns 22,000 shares of the company’s stock worth $764,000 after acquiring an additional 14,607 shares during the last quarter. Finally, ARS Investment Partners LLC lifted its holdings in shares of Biohaven by 47.8% in the 2nd quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after acquiring an additional 304,141 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Price Performance

NYSE BHVN opened at $46.06 on Monday. The company has a market capitalization of $4.66 billion, a PE ratio of -4.93 and a beta of 1.24. The company has a fifty day moving average of $49.65 and a 200 day moving average of $41.55. Biohaven has a 1 year low of $26.80 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Research analysts expect that Biohaven will post -8.85 earnings per share for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.